These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 25567324

  • 21. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP, Posthouwer D, Fischer K, van den Berg HM.
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S, Cannavò A, Gouw SC, Rosendaal FR, van der Bom JG.
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
    Montalvão SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC.
    Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
    [Abstract] [Full Text] [Related]

  • 30. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
    Rota M, Cortesi PA, Steinitz-Trost KN, Reininger AJ, Gringeri A, Mantovani LG.
    Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
    [Abstract] [Full Text] [Related]

  • 31. [Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data collection].
    Siegmund B, Pollmann H, Richter H, Orlovic M, Gottstein S, Klamroth R.
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S37-9. PubMed ID: 21042673
    [Abstract] [Full Text] [Related]

  • 32. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
    Ettingshausen CE, Kreuz W.
    Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
    [Abstract] [Full Text] [Related]

  • 33. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
    Scharrer I, Bray GL, Neutzling O.
    Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
    [Abstract] [Full Text] [Related]

  • 34. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
    Volkers P, Hanschmann KM, Calvez T, Chambost H, Collins PW, Demiguel V, Hart DP, Hay CRM, Goudemand J, Ljung R, Palmer BP, Santagostino E, van Hardeveld EM, van den Berg M, Keller-Stanislawski B.
    Haemophilia; 2019 May; 25(3):398-407. PubMed ID: 31066174
    [Abstract] [Full Text] [Related]

  • 35. The natural history of mild haemophilia: a 30-year single centre experience.
    Tagliaferri A, Di Perna C, Riccardi F, Pattacini C, Rivolta GF, Franchini M.
    Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
    [Abstract] [Full Text] [Related]

  • 36. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
    Kim SK, Yoo KY, Lee KS, Hwang T, Choi YM, Choi EJ, Park SK.
    J Korean Med Sci; 2018 Jan 01; 33(1):e5. PubMed ID: 29215814
    [Abstract] [Full Text] [Related]

  • 37. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
    Borhany M, Kumari M, Shamsi T, Naz A, Farzana T.
    J Coll Physicians Surg Pak; 2012 May 01; 22(5):289-93. PubMed ID: 22538032
    [Abstract] [Full Text] [Related]

  • 38. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study.
    Ewenstein BM, Gomperts ED, Pearson S, O'Banion ME.
    Haemophilia; 2004 Sep 01; 10(5):491-8. PubMed ID: 15357776
    [Abstract] [Full Text] [Related]

  • 39. EUHASS: The European Haemophilia Safety Surveillance system.
    Makris M, Calizzani G, Fischer K, Gilman EA, Hay CR, Lassila R, Lambert T, Ludlam CA, Mannucci PM.
    Thromb Res; 2011 Jan 01; 127 Suppl 2():S22-5. PubMed ID: 21193110
    [Abstract] [Full Text] [Related]

  • 40. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR, Misgav M, Ozelo M, Salek SZ, Veljkovic D, Recht M, Cerqueira M, Tiede A, Brand B, Mancuso ME, Seremetis S, Lindblom A, Martinowitz U.
    Haemophilia; 2013 Sep 01; 19(5):691-7. PubMed ID: 23647704
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.